METHOD, COMPOSITION AND KIT FOR SCREENING ALK OR ROS-1 KINASE INHIBITOR

• US 20200132672A1
• Filed: 05/10/2019
• Published: 04/30/2020
• Est. Priority Date: 10/31/2018
• Status: Active Grant

• Current Assignee: Korea Advanced Institute of Science and Technology
• Original Assignee: Korea Advanced Institute of Science and Technology
• Inventors: JUNG, Byung Hwa, LEE, Hyun Beom, YOON, Naeun
• Granted Patent: US 11,506,654 B2
• Time in Patent Office: Days
• CPC Class Codes: C12Q 1/485 involving kinase
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity
• CPC Class Codes: G01N 33/5038 involving detection of metabolites per se
• CPC Class Codes: G01N 33/57415 of breast
• CPC Class Codes: G01N 33/57419 of colon
• CPC Class Codes: G01N 33/57423 of lung
• CPC Class Codes: G01N 33/57438 of liver, pancreas or kidney

Abstract

A method, a composition and a kit for screening an ALK or ROS-1 kinase inhibitor are disclosed in the present specification. In an aspect, by the method, composition and kit for screening an ALK or ROS-1 kinase inhibitor according to the present disclosure, it is possible to conduct simultaneous quantitative and qualitative analysis and faster screening of a larger number of candidate substances as compared with conventional molecular biological experimental methods and to grasp the overall level of change in a plurality of different metabolites in a cell line by candidate substances of ALK or ROS-1 kinase inhibitor and thus the screening efficiency for drugs which exert an ALK or ROS-1 kinase inhibitory effect is excellent. Consequently, the present disclosure has an advantage of being able to be used in various ways in the development of new drugs which exert an ALK or ROS-1 kinase inhibitory effect.

Claims

1. A method for screening an ALK or ROS-1 kinase inhibitor, comprising:

treating a cell line with a candidate substance;

measuring a level of one or more metabolites selected from a group consisting of adenosine, AMP and cAMP in the cell line treated with the candidate substance; and

comparing the measured level of one or more metabolites selected from a group consisting of adenosine, AMP and cAMP with a level before being treated with the candidate substance.

2. The method according to claim 1, wherein the ALK or ROS-1 kinase inhibitor is a drug for cancer treatment.

3. The method according to claim 1, wherein the ALK or ROS-1 kinase inhibitor is one or more of a drug for lung cancer treatment, a drug for breast cancer treatment, a drug for brain cancer treatment, a drug for pancreatic cancer treatment and a drug for colorectal cancer treatment.

4. The method according to claim 1, wherein the cell line is one or more of a lung carcinoma cell line, a breast carcinoma cell line, a brain cancer cell line, a pancreatic cancer cell line and a colorectal cancer cell line.

5. The method according to claim 4, wherein the lung carcinoma cell line is a non-small cell lung carcinoma cell line.

6. The method according to claim 4, wherein the breast cancer cell line is a carcinoma in situ of breast cell line.

7. The method according to claim 1, further comprising conducting multivariate analysis of the measured level of metabolites.

8. The method according to claim 1, further comprising judging a candidate substance to be suitable as an ALK or ROS-1 kinase inhibitor when a content of adenosine or cAMP in the cell line is higher than that before being treated with the candidate substance and a candidate substance to be unsuitable as an ALK or ROS-1 kinase inhibitor when a content of adenosine or cAMP in the cell line is lower than or equal to that before being treated with the candidate substance.

9. The method according to claim 1, further comprising judging a candidate substance to be suitable as an ALK or ROS-1 kinase inhibitor when a content of AMP in the cell line is lower than that before being treated with the candidate substance and a candidate substance to be unsuitable as an ALK or ROS-1 kinase inhibitor when a content of AMP in the cell line is higher than or equal to that before being treated with the candidate substance.

10. A kit for screening an ALK or ROS-1 kinase inhibitor, comprising a level measuring unit of one or more metabolites selected from a group consisting of adenosine, AMP and cAMP.

11. The kit according to claim 10, wherein the ALK or ROS-1 kinase inhibitor is a drug for cancer treatment.

12. The kit according to claim 10, wherein the ALK or ROS-1 kinase inhibitor is one or more of a drug for lung cancer treatment, a drug for breast cancer treatment, a drug for brain cancer treatment, a drug for pancreatic cancer treatment and a drug for colorectal cancer treatment.

13. The kit according to claim 10, further comprising one or more cell lines selected from the group consisting of a lung carcinoma cell line, a breast carcinoma cell line, a brain cancer cell line, a pancreatic cancer cell line and a colorectal cancer cell line.

14. The kit according to claim 13, wherein the lung carcinoma cell line is a non-small cell lung carcinoma cell line.

15. The kit according to claim 13, wherein the breast carcinoma cell line is a carcinoma in situ of breast cell line.

16. The kit according to claim 10, further comprising a multivariate analysis system for analyzing levels of metabolites measured in the level measuring unit.